Literature DB >> 23519541

Agomelatine-induced hepatotoxicity.

Matej Štuhec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23519541     DOI： 10.1007/s00508-013-0344-0

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  10 in total

1.  IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 1. The concept of reference procedures for the measurement of catalytic activity concentrations of enzymes.

Authors:  Lothar Siekmann; Roberto Bonora; Carl A Burtis; Ferruccio Ceriotti; Pascale Clerc-Renaud; Georges Férard; Carlo A Ferrero; Jean-Claude Forest; Paul F H Franck; F Javier Gella; Wieland Hoelzel; Poul Jørgen Jørgensen; Takashi Kanno; Art Kessner; Rainer Klauke; Nina Kristiansen; Jean-Marc Lessinger; Thomas P J Linsinger; Hideo Misaki; Mathias M Mueller; Mauro Panteghini; Jean Pauwels; Françoise Schiele; Heinz G Schimmel; Arlette Vialle; Gerhard Weidemann; Gerhard Schumann
Journal:  Clin Chem Lab Med       Date:  2002-06       Impact factor: 3.694

2.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

3.  IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase.

Authors:  Gerhard Schumann; Roberto Bonora; Ferruccio Ceriotti; Georges Férard; Carlo A Ferrero; Paul F H Franck; F Javier Gella; Wieland Hoelzel; Poul Jørgen Jørgensen; Takashi Kanno; Art Kessner; Rainer Klauke; Nina Kristiansen; Jean-Marc Lessinger; Thomas P J Linsinger; Hideo Misaki; Mauro Panteghini; Jean Pauwels; Françoise Schiele; Heinz G Schimmel; Gerhard Weidemann; Lothar Siekmann
Journal:  Clin Chem Lab Med       Date:  2002-07       Impact factor: 3.694

4.  Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Authors:  Siegfried Kasper; Göran Hajak; Katharina Wulff; Witte J G Hoogendijk; Angel Luis Montejo; Enrico Smeraldi; Janusz K Rybakowski; Maria-Antonia Quera-Salva; Anna M Wirz-Justice; Françoise Picarel-Blanchot; Franck J Baylé
Journal:  J Clin Psychiatry       Date:  2010-02       Impact factor: 4.384

5.  Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  John Zajecka; Alan Schatzberg; Stephen Stahl; Amy Shah; Angelika Caputo; Anke Post
Journal:  J Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.153

Review 6.  A benefit-risk assessment of agomelatine in the treatment of major depression.

Authors:  Robert H Howland
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

7.  Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

Authors:  Frédéric Rouillon
Journal:  Int Clin Psychopharmacol       Date:  2006-02       Impact factor: 1.659

Review 8.  Agomelatine: a novel pharmacological approach to treating depression.

Authors:  Richard T Owen
Journal:  Drugs Today (Barc)       Date:  2009-08       Impact factor: 2.245

9.  Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients.

Authors:  Helge Müller; Frank Seifert; Juan-Manuel Maler; Johannes Kornhuber; Wolfgang Sperling
Journal:  Singapore Med J       Date:  2012-11       Impact factor: 1.858

10.  Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.

Authors:  Domenico De Berardis; Nicola Serroni; Stefano Marini; Giovanni Martinotti; Francesca Ferri; Gaetano Callista; Raffaella La Rovere; Francesco Saverio Moschetta; Massimo Di Giannantonio
Journal:  Case Rep Psychiatry       Date:  2012-10-09
  10 in total
  6 in total

Review 1.  Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.

Authors:  A Irem Sonmez; Ammar Almorsy; Laura B Ramsey; Jeffrey R Strawn; Paul E Croarkin
Journal:  Depress Anxiety       Date:  2020-05-17       Impact factor: 6.505

Review 2.  Agomelatine: an agent against anhedonia and abulia?

Authors:  J Thome; P Foley
Journal:  J Neural Transm (Vienna)       Date:  2013-12-06       Impact factor: 3.575

Review 3.  Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.

Authors:  Matej Štuhec
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

4.  A systematic review of agomelatine-induced liver injury.

Authors:  Silka Dawn Freiesleben; Karolina Furczyk
Journal:  J Mol Psychiatry       Date:  2015-04-21

5.  Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.

Authors:  Maximilian Gahr
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

6.  Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.

Authors:  Matej Stuhec; Robert Oravecz
Journal:  Wien Klin Wochenschr       Date:  2015-09-24       Impact factor: 1.704
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.